Just appeared on facebook
Telix today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA-targeted radionuclide therapy.Label expansion means that Illuccix is now approved to select patients, with progressive metastatic castration-resistant prostate cancer, for treatment with 177-Lu vipivotide tetraxetan, the only PSMA-targeted lutetium therapy registered in Canada.Read more on our website here: https://bit.ly/3TR1hLF
Just appeared on facebookTelix today announces that Health...
-
- There are more pages in this discussion • 2,653 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$25.60 |
Change
0.820(3.31%) |
Mkt cap ! $8.659B | |||
| Open | High | Low | Value | Volume |
| $25.04 | $25.80 | $24.99 | $25.96M | 1.017M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1176 | $25.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $25.61 | 1596 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| TLX (ASX) Chart |